Objective To observe the clinical effect of Fuzheng Guben Lishui Recipe on intraperitoneal immune micro-environment in malignant ascites patients with spleen and kidney yang deficiency and its clinical efficacy.

Methods A total of 66 patients with advanced gastric cancer and spleen and kidney yang deficiency syndrome of malignant ascites were randomly divided into control group and treatment group, with 33 patients in per group. The control group was given intraperitoneal perfusion chemotherapy and the treatment group was given Fuzheng Guben Lishui Recipe and intraperitoneal perfusion chemotherapy. After 2 courses treatment, the peripheral blood T cell subsets, ascites immune cytokinesinterferon-γ(IFN-γ), interleukin-10(IL-10), ascites treatment efficacy and the incidence of toxic side reactions were observed and compared in two groups.

Results Before treatment, there were no significant differences in peripheral blood CD3⁺, CD4⁺, CD8⁺ and CD4⁺/CD8⁺ between two groups (P>0.05). After treatment, the peripheral blood CD3⁺, CD4⁺ and CD4⁺/CD8⁺ in the two groups were significantly increased(P < 0.05). Compared with the control group, the peripheral blood CD3⁺, CD4⁺ and CD4⁺/CD8⁺ in the treatment group were significantly increased (P < 0.05). After treatment, IFN-γ increased and IL-10 decreased in ascites of the treatment group compared with that before treatment, and the differences were statistically significant (P < 0.05). Compared with the control group, IFN-γ increased and IL-10 decreased in the treatment group, and the differences were statistically significant (P < 0.05). The effective rate of malignant ascites in the treatment group was 75.76%, which was higher than 51.52% in the control group (P < 0.05). Gastrointestinal reaction and myelosuppression occurred in both groups. The incidence of myelosuppression in the treatment group was 6.06%, which was lower than 24.24% in the control group, and the difference was statistically significant (P < 0.05).

Conclusion Fuzheng Guben Lishui Recipe can improve the intraperitoneal immune micro-environment in malignant ascites patients with spleen and kidney yang deficiency, improve the therapeutic efficacy of malignant ascites, and relieve bone marrow suppression due to intraperitoneal perfusion chemotherapy.